Is there increasing evidence that the risks of rhAPC may outweigh its benefits? [5]

Intensive Care Medicine

Volumn 33, Issue 8, 2007, Pages 1485-1486

  Plataki, Maria ^a   Vaporidi, Katerina ^a   Georgopoulos, Dimitris ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HEALTH SURVEY; HUMAN; LETTER; MEDICAL EDUCATION; MORTALITY; RISK; RISK BENEFIT ANALYSIS; SEPSIS; SURVIVAL; THERAPY DELAY; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ANTI-INFECTIVE AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RISK ASSESSMENT; SEPSIS;

EID: 34547107308     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0707-y     Document Type: Letter

References (8)

1. Eichacker PQ, Natanson C (2007) Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 33:396-399
2. Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 33:517-523
3. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33:426-434
4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Wesley Ely E, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
5. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266-2277
6. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 369:836-843
7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332-1341
8. Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. Novation